• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

    9/8/25 8:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENTX alert in real time by email

    EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide

    Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence

    Entera also Presented Promising Pharmacokinetic Data for Next-Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension

    JERUSALEM, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, today announced data selected for presentation at the American Society for Bone and Mineral Research ("ASBMR") 2025 Annual Meeting in Seattle, Washington, for its lead program EB613 which is in late stage clinical development for post-menopausal women with osteoporosis. It is estimated that 50 percent of women and 20 percent of men over the age of 50 are at risk of a fragility fractures and less than 30% of patients are adequately treated with available medications.

    "The data presented at ASBMR this year marks important progress for our EB613 program," said Miranda Toledano, Chief Executive Officer of Entera. "Available injectable anabolic treatments, while efficacious and recommended across medical guidelines, are only accessible to a minority of patients globally. Our EB613 program is being developed to address the treatment chasm in osteoporosis care with a viable anabolic treatment in tablet format for patients to adequately protect their bones."

    In the oral presentation titled "Effects of EB613 Tablets [Oral PTH(1-34)] on Trabecular and Cortical Bone Using 3D-DXA: Results from Phase 2 Study," Rachel B. Wagman, MD presented data using 3D-DXA modelling in a post-hoc analysis of EB613 Phase 2 results to look at the treatment's impact on trabecular and cortical bone. After 6 months of treatment, EB613 2.5 mg demonstrated significant increases in both trabecular and cortical bone parameters as compared with placebo. Mechanistically, the findings suggest that bone strengthening, and fracture resistance may occur rapidly with EB613.

    "The improvements across multiple parameters, including integral volumetric BMD, cortical thickness, and cortical surface BMD, suggest that there is an early strengthening effect with EB613 and a deterioration with placebo," said Dr. Wagman. "We look forward to studying the safety and efficacy of EB613 in Phase 3."

    • Increases in integral volumetric BMD of the TH and FN by 1.7% (p<0.08) and 2.6% (p<0.03), respectively
    • Increases in FN trabecular volumetric BMD by 4.4% vs. placebo (p<0.03) and increases in TH trabecular volumetric BMD by 2.8% (p=0.05 vs. baseline, NS compared with placebo)
    • Increases in cortical thickness at the TH and FN by 1.3% (p=0.04) and 1.7% (p=0.056), respectively Improvements in cortical surface BMD at the TH and FN by 1.5% and 2.1%, respectively (both p<0.05)

    In a poster presentation titled "Advancing Oral Anabolic Treatments for Osteoporosis: Pre-Clinical Data for Next-Gen EB613 Tablet Utilizing N-Tab™ Proprietary Technology," Entera presented preclinical data for its Next-Gen EB613 candidate. In a cross-over pharmacokinetic study in minipigs, a single 1.5 mg Next-Gen EB613 tablet demonstrated comparable PK to the current formulation of EB613, with identical AUClast and Tmax values (1.2 min*ng/ml and 20 min, respectively), and comparable Cmax. A Phase 1 clinical trial of Next-Gen EB613 is planned to begin in late 2025.

    About EB613

    Substantial evidence supports the efficacy of anabolic treatments over anti-resorptive drugs for lowering fracture risk in osteoporosis patients. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. EB613 (oral PTH (1-34)), is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. EB613 completed a phase 2, 6-month, 161-patient, placebo-controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose-proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increased lumbar spine, total hip, and femoral neck BMD.

    About Entera Bio

    Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company's most advanced product candidate, EB613 (oral PTH(1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

    Cautionary Statement Regarding Forward Looking Statements

    Various statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera's forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's ability to establish and maintain development and commercialization collaborations; Entera's operation as a development stage company with limited operating history; Entera's competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Cautionary Statement Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's most recent Annual Report on Form 10-K filed with the SEC, as well as Entera's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.



    Contact:
    
    Entera Bio:
    
    Ms. Miranda Toledano
    Chief Executive Officer
    Entera Bio
    Email: [email protected]

    Primary Logo

    Get the next $ENTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Entera Bio Ltd.

    10-Q - Entera Bio Ltd. (0001638097) (Filer)

    8/8/25 4:07:06 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Entera Bio Ltd. (0001638097) (Filer)

    8/8/25 4:05:36 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Entera Bio Ltd. (0001638097) (Filer)

    7/28/25 7:35:24 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

    EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence Entera also Presented Promising Pharmacokinetic Data for Next-Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension JERUSALEM, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, today announced data selected for presentation at the American Society for Bone and

    9/8/25 8:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

    Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone, and Next-Gen EB613 PK/PD data slated for oral and poster presentations at ASBMRShort Bowel Syndome and Rare GI Disorders: PK/PD of oral GLP-2 tablet candidate poster presentation at ESPENCorporate Overview at H.C. Wainwright Investor Conference JERUSALEM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, today announced that the Company will present data across three key programs during September 2025. Details on the presentations are available below: Ame

    8/28/25 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

    FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies and next-gen EB613 expected to enter Phase 1 in November 2025Strong momentum across OPKO collaboration with obesity program showing promising preclinical data; and EB612 oral PTH directed hypoparathyroidism program candidate validationStrong balance sheet provides runway through mid-Q3 2026, including dedicated OPKO collaboration funding JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio

    8/8/25 4:05:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Toledano Miranda Jayne was granted 180,702 units of Ordinary Shares, increasing direct ownership by 77% to 415,575 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    7/18/25 4:37:05 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief of R&D Burshtein Gregory was granted 26,316 units of Ordinary Shares, increasing direct ownership by 35% to 101,442 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    7/18/25 4:35:58 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Yaacov-Garbeli Dana was granted 26,316 units of Ordinary Shares (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    7/18/25 4:34:36 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Taitel Haya bought $9,405 worth of Ordinary Shares (9,500 units at $0.99), increasing direct ownership by 37% to 35,115 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/16/24 8:00:12 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taitel Haya bought $5,864 worth of Ordinary Shares (7,615 units at $0.77), increasing direct ownership by 42% to 25,615 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/11/24 6:14:57 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lieberman Gerald M bought $17,006 worth of Ordinary Shares (23,952 units at $0.71), increasing direct ownership by 12% to 226,961 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    12/27/23 5:00:37 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Entera Bio with a new price target

    B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00

    6/16/21 6:22:06 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aegis Capital initiated coverage on Entera Bio with a new price target

    Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00

    3/22/21 10:40:44 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group reiterated coverage on Entera Bio with a new price target

    Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously

    3/11/21 12:09:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Leadership Updates

    Live Leadership Updates

    View All

    Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

    JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

    5/9/25 4:05:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

    JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

    5/15/24 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

    JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd

    6/7/23 7:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Financials

    Live finance-specific insights

    View All

    Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

    JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)

    11/10/22 4:15:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

    Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT  BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o

    5/12/22 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio to Report First Quarter 2022 Financial Results on May 12

    BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a

    4/28/22 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    11/20/24 1:48:55 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    8/20/24 6:01:17 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    1/16/24 10:45:49 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care